Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis ( MAGMA ) Trial-Reference-Cited by-同舟云学术

Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis ( MAGMA ) Trial

Published:2017-05-26 Issue:9 Volume:40 Page:633-640
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Rajagopalan Sanjay¹²,Alaiti M. Amer¹^ORCID,Broadwater Kylene²,Goud Aditya¹,Gaztanaga Juan³,Connelly Kim⁴,Fares Anas¹,Shirazian Shayan⁵,Kreatsoulas Catherine⁶,Farkouh Michael⁷,Dobre Mirela⁸,Fink Jeffrey C.²,Weir Matthew R.²

Affiliation:

1. Division of Cardiovascular Medicine, Harrington Heart and Vascular InstituteUniversity Hospitals, Cleveland Medical Center Ohio

2. University of Maryland School of Medicine Baltimore

3. Division of Internal Medicine, Department of CardiologyNYU Winthrop Hospital Mineola New York

4. Keenan Research Centre for Biomedical ScienceSt. Michael's Hospital Toronto Ontario Canada

5. Division of Nephrology and Hypertension, Diabetes and Obesity Research CenterNYU Winthrop Hospital Mineola New York

6. Harvard School of Public HealthHarvard University Cambridge Massachusetts

7. Department of Cardiology, Peter Munk Cardiac CentreUniversity Health Network Toronto Ontario Canada

8. Division of NephrologyUniversity Hospitals, Cleveland Medical Center Ohio

Funder

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.22718

Reference40 articles.

1. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor

2. Specificity in mineralocorticoid versus glucocorticoid action

3. Mineralocorticoid selectivity: Molecular and cellular aspects

4. Mineralocorticoid Action: Target Tissue Specificity Is Enzyme, Not Receptor, Mediated

5. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial;Circulation;2024-08-27

2. Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus With Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials;Journal of Cardiovascular Pharmacology;2023-01

3. Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease;American Journal of Physiology-Cell Physiology;2023-01-01

4. Elevated microRNA-135b-5p relieves neuronal injury and inflammation in post-stroke cognitive impairment by targeting NR3C2;International Journal of Neuroscience;2020-08-04

5. Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm;Kidney360;2020-07-23